Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.59 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.53 |
| ▸ | GCGR | P47871 | 2/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.53 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422522 | 1.00 | MAPK14 (0.59) | MAPK14CSNK1DPTGER1ALOX5MAPK13 | |
| SCHEMBL4426390 | 0.88 | RAF1 (0.57) | MAPK14CSNK1DPTGER1ALOX5MAPK13 | |
| SCHEMBL7228732 | 0.88 | RAF1 (0.57) | MAPK14CSNK1DPTGER1ALOX5MAPK13 | |
| SCHEMBL7445283 | 0.88 | MAPK14 (0.58) | MAPK14CSNK1DPTGER1ALOX5MAPK13 | |
| SCHEMBL4426392 | 0.85 | MAPK14 (0.52) | MAPK14CSNK1DPTGER1ALOX5MAPK13 | |
| SCHEMBL8488765 | 0.81 | MAPK14 (0.55) | MAPK14CSNK1DPTGER1ALOX5MAPK13 | |
| SCHEMBL4429243 | 0.81 | TEK (0.60) | MAPK14CSNK1DPTGER1ALOX5MAPK13 | |
| SCHEMBL5082102 | 0.81 | TEK (0.60) | MAPK14CSNK1DPTGER1ALOX5MAPK13 | |
| SCHEMBL5488836 | 0.80 | ALOX5 (0.47) | MAPK14PTGER1ALOX5MAPK13GCGR | |
| SCHEMBL822678 | 0.80 | PTGER1 (0.56) | MAPK14PTGER1ALOX5MAPK13GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | claimed |
| US-7351729-B2 | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070149571-A1 | Combination therapy for treating or managing acute myelocytic leukemia | SIGNAL PHARMACEUTICALS, LLC | 2007-06-28 | — | — | US | disclosed |
| US-20040067953-A1 | Combination therapy for treating, preventing or managing proliferative disorders and cancers | SIGNAL PHARMACEUTICALS, LLC | 2004-04-08 | — | — | US | disclosed |
| US-6645989-B2 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-6235760-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2001-05-22 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| CN-1083473-A | New imidazolium compounds and pharmaceutical composition thereof | SMITHKLINE BEECHAM CORP (US) | 1994-03-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149571-A1 | Combination therapy for treating or managing acute myelocytic leukemia | MCL1, ATF1, MAP3K5 | MAPK14 69/4885CSNK1D 736/4885PTGER1 1013/4885 |
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | MAPK14 3769/4885CSNK1D 1702/4885PTGER1 2445/4885 |
| US-20040067953-A1 | Combination therapy for treating, preventing or managing proliferative disorders and cancers | MAP3K1, MAP3K2, MAP2K2 | MAPK14 72/4885CSNK1D 540/4885PTGER1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.